Isolation of tumor-derived immunoglobulin-idiotype from peripheral blood mononuclear cells in a B-cell lymphoma patient with minimal disease.

L Alvarez-Vallina, A Plaza, M Kreisler, R Cabrera, M N Fernández, F Díaz-Espada
{"title":"Isolation of tumor-derived immunoglobulin-idiotype from peripheral blood mononuclear cells in a B-cell lymphoma patient with minimal disease.","authors":"L Alvarez-Vallina,&nbsp;A Plaza,&nbsp;M Kreisler,&nbsp;R Cabrera,&nbsp;M N Fernández,&nbsp;F Díaz-Espada","doi":"10.1097/00002371-199504000-00008","DOIUrl":null,"url":null,"abstract":"<p><p>Active immunization with autologous idiotypic immunoglobulin, obtained by somatic fusion techniques, has been shown to be a useful alternative treatment in patients with B-cell lymphoma. Nevertheless, the requirement for biopsy specimens to obtain lymphoma cells could be a limitation to this therapeutic strategy. We address the question of whether peripheral blood samples containing small amounts of tumor cells can be used as appropriate fusion partners to rescue tumor-derived idiotypic proteins. In this report, we show that hybrid cells can be obtained from somatic fusions of K6H6/B5 heterohybridoma with lymphoma cells obtained from both lymph node (LN) and peripheral blood mononuclear cells (PBMC) containing only minor amounts of tumor cells. Some hybrid cells obtained from LN or PBMC fusions present an immunoglobulin (Ig) heavy-chain gene rearrangement identical with that of the original tumor and secrete identical Ig protein containing the expected H and L chains.</p>","PeriodicalId":79346,"journal":{"name":"Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy","volume":"17 3","pages":"194-8"},"PeriodicalIF":0.0000,"publicationDate":"1995-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00002371-199504000-00008","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00002371-199504000-00008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Active immunization with autologous idiotypic immunoglobulin, obtained by somatic fusion techniques, has been shown to be a useful alternative treatment in patients with B-cell lymphoma. Nevertheless, the requirement for biopsy specimens to obtain lymphoma cells could be a limitation to this therapeutic strategy. We address the question of whether peripheral blood samples containing small amounts of tumor cells can be used as appropriate fusion partners to rescue tumor-derived idiotypic proteins. In this report, we show that hybrid cells can be obtained from somatic fusions of K6H6/B5 heterohybridoma with lymphoma cells obtained from both lymph node (LN) and peripheral blood mononuclear cells (PBMC) containing only minor amounts of tumor cells. Some hybrid cells obtained from LN or PBMC fusions present an immunoglobulin (Ig) heavy-chain gene rearrangement identical with that of the original tumor and secrete identical Ig protein containing the expected H and L chains.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
b细胞淋巴瘤患者外周血单个核细胞中肿瘤源性免疫球蛋白独特型的分离
通过体细胞融合技术获得的自体独特型免疫球蛋白的主动免疫已被证明是b细胞淋巴瘤患者的一种有用的替代治疗方法。然而,对活检标本获得淋巴瘤细胞的要求可能是这种治疗策略的限制。我们解决了含有少量肿瘤细胞的外周血样本是否可以作为合适的融合伙伴来拯救肿瘤来源的独特型蛋白的问题。在这篇报道中,我们证明了K6H6/B5异杂交瘤与淋巴细胞(LN)和外周血单核细胞(PBMC)中仅含有少量肿瘤细胞的淋巴瘤细胞的体细胞融合可以获得杂交细胞。LN或PBMC融合获得的一些杂交细胞表现出与原始肿瘤相同的免疫球蛋白(Ig)重链基因重排,并分泌含有预期H链和L链的相同Ig蛋白。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. HLA class I antigens in Japanese patients with melanoma. Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1